Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lundbeck Defends Its Escitalopram Patent In Denmark, But Not In Spain

This article was originally published in The Pink Sheet Daily

Executive Summary

Lundbeck's top-selling product, Cipralex, is responsible for more than half its sales, but faces generic competition in Spain.
Advertisement

Related Content

Lundbeck’s New Partners: Research With Genmab, Marketing With Merck
Lundbeck’s New Partners: Research With Genmab, Marketing With Merck
Lundbeck's New Partnering Focus: Link Up With Genmab On Research And Merck On Marketing Sycrest
Lundbeck's New Partnering Focus: Link Up With Genmab On Research And Merck On Marketing Sycrest
FDA Complete Response Slows Down, But Won't Stop, Lundbeck's Serdolect
Lundbeck Looks To Replace Lexapro Earnings Through Ovation Purchase
Lundbeck Looks To Replace Lexapro Earnings Through Ovation Purchase

Topics

Advertisement
UsernamePublicRestriction

Register

PS070505

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel